

Table 1.14

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Both Sexes, 17 SEER Areas, 2006-2008

| Site | All Races | | | Whites | | | Blacks | | |
|--|-----------|------------------|--|---------|------------------|--|---------|------------------|--|
| | Percent | (95% C.I.) | | Percent | (95% C.I.) | | Percent | (95% C.I.) | |
| All Sites | 41.21 | (41.11, 41.30) | | 41.56 | (41.46, 41.66) | | 37.24 | (36.96, 37.53) | |
| Invasive and In Situ | 43.53 | (43.44, 43.63) | | 43.91 | (43.81, 44.02) | | 38.60 | (38.31, 38.90) | |
| Oral Cavity and Pharynx | 1.05 | (1.03, 1.06) | | 1.08 | (1.06, 1.10) | | 0.79 | (0.75, 0.83) | |
| Esophagus | 0.51 | (0.50, 0.52) | | 0.52 | (0.51, 0.53) | | 0.46 | (0.43, 0.50) | |
| Stomach | 0.87 | (0.86, 0.89) | | 0.76 | (0.75, 0.77) | | 1.14 | (1.09, 1.20) | |
| Colon and Rectum | 5.08 | (5.05, 5.12) | | 5.03 | (4.99, 5.06) | | 5.08 | (4.98, 5.19) | |
| Invasive and In Situ | 5.31 | (5.28, 5.34) | | 5.24 | (5.21, 5.28) | | 5.37 | (5.26, 5.48) | |
| Liver and Intrahepatic Bile Duct | 0.80 | (0.79, 0.81) | | 0.69 | (0.68, 0.70) | | 0.84 | (0.80, 0.88) | |
| Pancreas | 1.45 | (1.43, 1.47) | | 1.44 | (1.42, 1.46) | | 1.54 | (1.48, 1.60) | |
| Larynx | 0.36 | (0.35, 0.37) | | 0.37 | (0.36, 0.38) | | 0.46 | (0.43, 0.49) | |
| Invasive and In Situ | 0.39 | (0.38, 0.40) | | 0.40 | (0.39, 0.41) | | 0.48 | (0.46, 0.52) | |
| Lung and Bronchus | 6.94 | (6.90, 6.98) | | 7.12 | (7.08, 7.17) | | 6.59 | (6.47, 6.71) | |
| Melanoma of the Skin | 1.97 | (1.95, 1.98) | | 2.28 | (2.26, 2.30) | | 0.09 | (0.07, 0.10) | |
| Invasive and In Situ | 3.18 | (3.16, 3.21) | | 3.62 | (3.59, 3.65) | | 0.11 | (0.09, 0.13) | |
| Breast | 6.37 | (6.33, 6.40) | | 6.51 | (6.47, 6.54) | | 5.63 | (5.52, 5.73) | |
| Invasive and In Situ | 7.64 | (7.60, 7.67) | | 7.77 | (7.73, 7.81) | | 6.78 | (6.66, 6.89) | |
| Urinary Bladder (Invasive and In Situ) | 2.41 | (2.38, 2.43) | | 2.60 | (2.58, 2.63) | | 1.18 | (1.13, 1.24) | |
| Kidney and Renal Pelvis | 1.56 | (1.55, 1.58) | | 1.62 | (1.60, 1.64) | | 1.44 | (1.39, 1.50) | |
| Brain and Other Nervous System | 0.61 | (0.60, 0.62) | | 0.66 | (0.65, 0.68) | | 0.33 | (0.30, 0.35) | |
| Thyroid | 0.97 | (0.95, 0.98) | | 1.01 | (1.00, 1.02) | | 0.53 | (0.50, 0.56) | |
| Hodgkin Lymphoma | 0.23 | (0.23, 0.24) | | 0.25 | (0.24, 0.26) | | 0.20 | (0.19, 0.22) | |
| Non-Hodgkin Lymphoma | 2.13 | (2.11, 2.15) | | 2.24 | (2.22, 2.27) | | 1.21 | (1.17, 1.26) | |
| Myeloma | 0.65 | (0.64, 0.66) | | 0.60 | (0.59, 0.62) | | 1.08 | (1.04, 1.14) | |
| Leukemia | 1.34 | (1.32, 1.36) | | 1.41 | (1.39, 1.43) | | 0.85 | (0.81, 0.90) | |
| Acute Lymphocytic Leukemia | 0.13 | (0.12, 0.13) | | 0.14 | (0.13, 0.14) | | 0.07 | (0.06, 0.08) | |
| Chronic Lymphocytic Leukemia | 0.50 | (0.49, 0.51) | | 0.53 | (0.52, 0.54) | | 0.27 | (0.24, 0.29) | |
| Acute Myeloid Leukemia | 0.39 | (0.38, 0.40) | | 0.40 | (0.39, 0.41) | | 0.28 | (0.26, 0.31) | |
| Chronic Myeloid Leukemia | 0.16 | (0.16, 0.17) | | 0.17 | (0.16, 0.18) | | 0.13 | (0.11, 0.14) | |
| Kaposi Sarcoma | 0.05 | (0.04, 0.05) | | 0.04 | (0.04, 0.05) | | 0.08 | (0.07, 0.09) | |
| Mesothelioma | 0.12 | (0.12, 0.13) | | 0.14 | (0.13, 0.14) | | 0.06 | (0.05, 0.07) | |

Devcan Version 6.6.0, October 2011, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.14 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Both Sexes, 17 SEER Areas, 2006-2008

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|--|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 35.65 (35.27, 36.03) | 27.74 (26.60, 28.99) | 36.97 (36.64, 37.32) |
| Invasive and In Situ | 37.11 (36.73, 37.50) | 28.45 (27.30, 29.71) | 38.25 (37.91, 38.60) |
| Oral Cavity and Pharynx | 0.87 (0.82, 0.93) | 0.79 (0.56, 1.18) | 0.70 (0.66, 0.75) |
| Esophagus | 0.36 (0.32, 0.40) | 0.48 (0.35, 0.78) | 0.34 (0.31, 0.38) |
| Stomach | 1.85 (1.76, 1.95) | 1.02 (0.82, 1.36) | 1.47 (1.40, 1.54) |
| Colon and Rectum | 5.24 (5.10, 5.40) | 3.98 (3.55, 4.53) | 4.73 (4.60, 4.86) |
| Invasive and In Situ | 5.44 (5.29, 5.60) | 4.13 (3.70, 4.69) | 4.93 (4.80, 5.06) |
| Liver and Intrahepatic Bile Duct | 1.88 (1.80, 1.97) | 1.23 (1.03, 1.59) | 1.38 (1.31, 1.45) |
| Pancreas | 1.56 (1.47, 1.67) | 1.18 (0.95, 1.56) | 1.55 (1.47, 1.63) |
| Larynx | 0.16 (0.13, 0.20) | 0.19 (0.12, 0.46) | 0.28 (0.26, 0.32) |
| Invasive and In Situ | 0.17 (0.14, 0.21) | 0.20 (0.13, 0.47) | 0.30 (0.28, 0.34) |
| Lung and Bronchus | 5.63 (5.47, 5.80) | 4.56 (4.09, 5.16) | 4.26 (4.14, 4.39) |
| Melanoma of the Skin | 0.15 (0.13, 0.18) | 0.30 (0.21, 0.58) | 0.50 (0.46, 0.54) |
| Invasive and In Situ | 0.19 (0.16, 0.22) | 0.51 (0.38, 0.81) | 0.73 (0.68, 0.79) |
| Breast | 5.31 (5.19, 5.44) | 3.64 (3.29, 4.12) | 5.06 (4.95, 5.18) |
| Invasive and In Situ | 6.67 (6.54, 6.81) | 4.13 (3.76, 4.63) | 5.96 (5.84, 6.08) |
| Urinary Bladder (Invasive and In Situ) | 1.39 (1.31, 1.48) | 0.82 (0.64, 1.17) | 1.56 (1.49, 1.65) |
| Kidney and Renal Pelvis | 1.04 (0.98, 1.10) | 1.84 (1.55, 2.27) | 1.68 (1.62, 1.75) |
| Brain and Other Nervous System | 0.40 (0.36, 0.45) | 0.32 (0.23, 0.58) | 0.54 (0.50, 0.58) |
| Thyroid | 1.08 (1.03, 1.14) | 0.49 (0.39, 0.76) | 0.89 (0.85, 0.94) |
| Hodgkin Lymphoma | 0.12 (0.11, 0.15) | 0.08 (0.03, 0.35) | 0.23 (0.21, 0.26) |
| Non-Hodgkin Lymphoma | 1.79 (1.70, 1.89) | 1.17 (0.95, 1.53) | 2.05 (1.97, 2.14) |
| Myeloma | 0.47 (0.43, 0.52) | 0.45 (0.28, 0.80) | 0.65 (0.60, 0.70) |
| Leukemia | 0.90 (0.84, 0.97) | 0.69 (0.53, 1.00) | 1.10 (1.05, 1.16) |
| Acute Lymphocytic Leukemia | 0.11 (0.09, 0.14) | 0.07 (0.04, 0.33) | 0.19 (0.18, 0.21) |
| Chronic Lymphocytic Leukemia | 0.16 (0.13, 0.20) | 0.12 (0.06, 0.39) | 0.26 (0.23, 0.30) |
| Acute Myeloid Leukemia | 0.41 (0.37, 0.46) | 0.25 (0.17, 0.52) | 0.34 (0.31, 0.38) |
| Chronic Myeloid Leukemia | 0.13 (0.11, 0.15) | 0.13 (0.06, 0.40) | 0.15 (0.13, 0.18) |
| Kaposi Sarcoma | 0.02 (0.01, 0.04) | 0.02 (0.00, 0.29) | 0.07 (0.05, 0.09) |
| Mesothelioma | 0.05 (0.04, 0.07) | 0.11 (0.05, 0.38) | 0.12 (0.10, 0.15) |

Devcan Version 6.6.0, October 2011, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

^a Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.15

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Males, 17 SEER Areas, 2006-2008

| Site | All Races | | Whites | | Blacks | |
|--|-----------|------------------|---------|------------------|---------|------------------|
| | Percent | (95% C.I.) | Percent | (95% C.I.) | Percent | (95% C.I.) |
| All Sites | 44.85 | (44.70, 44.99) | 44.77 | (44.61, 44.93) | 41.59 | (41.14, 42.04) |
| Invasive and In Situ | 46.20 | (46.05, 46.35) | 46.16 | (46.00, 46.32) | 41.92 | (41.47, 42.37) |
| Oral Cavity and Pharynx | 1.45 | (1.43, 1.48) | 1.49 | (1.47, 1.52) | 1.14 | (1.08, 1.21) |
| Esophagus | 0.79 | (0.78, 0.81) | 0.83 | (0.81, 0.85) | 0.68 | (0.63, 0.74) |
| Stomach | 1.10 | (1.07, 1.12) | 0.97 | (0.95, 1.00) | 1.37 | (1.28, 1.45) |
| Colon and Rectum | 5.27 | (5.22, 5.32) | 5.24 | (5.18, 5.29) | 5.02 | (4.87, 5.18) |
| Invasive and In Situ | 5.52 | (5.47, 5.57) | 5.48 | (5.43, 5.54) | 5.31 | (5.15, 5.47) |
| Liver and Intrahepatic Bile Duct | 1.13 | (1.11, 1.15) | 0.97 | (0.95, 1.00) | 1.24 | (1.17, 1.31) |
| Pancreas | 1.45 | (1.43, 1.48) | 1.46 | (1.44, 1.49) | 1.39 | (1.31, 1.47) |
| Larynx | 0.60 | (0.58, 0.62) | 0.61 | (0.59, 0.62) | 0.78 | (0.72, 0.84) |
| Invasive and In Situ | 0.65 | (0.63, 0.66) | 0.65 | (0.64, 0.67) | 0.83 | (0.77, 0.90) |
| Lung and Bronchus | 7.66 | (7.60, 7.72) | 7.71 | (7.65, 7.78) | 7.80 | (7.61, 7.99) |
| Melanoma of the Skin | 2.43 | (2.40, 2.46) | 2.80 | (2.76, 2.84) | 0.08 | (0.06, 0.10) |
| Invasive and In Situ | 3.91 | (3.87, 3.95) | 4.43 | (4.38, 4.48) | 0.10 | (0.08, 0.13) |
| Breast | 0.13 | (0.12, 0.13) | 0.13 | (0.12, 0.13) | 0.14 | (0.12, 0.17) |
| Invasive and In Situ | 0.14 | (0.13, 0.15) | 0.14 | (0.13, 0.15) | 0.16 | (0.13, 0.19) |
| Prostate | 16.48 | (16.39, 16.56) | 15.89 | (15.80, 15.99) | 19.10 | (18.81, 19.39) |
| Testis | 0.37 | (0.36, 0.38) | 0.44 | (0.43, 0.45) | 0.09 | (0.08, 0.11) |
| Urinary Bladder (Invasive and In Situ) | 3.84 | (3.79, 3.88) | 4.16 | (4.11, 4.21) | 1.65 | (1.55, 1.74) |
| Kidney and Renal Pelvis | 1.97 | (1.94, 2.00) | 2.04 | (2.01, 2.07) | 1.75 | (1.67, 1.84) |
| Brain and Other Nervous System | 0.68 | (0.67, 0.70) | 0.75 | (0.73, 0.77) | 0.36 | (0.32, 0.40) |
| Thyroid | 0.50 | (0.49, 0.51) | 0.53 | (0.51, 0.54) | 0.25 | (0.22, 0.28) |
| Hodgkin Lymphoma | 0.25 | (0.25, 0.26) | 0.27 | (0.26, 0.28) | 0.23 | (0.20, 0.25) |
| Non-Hodgkin Lymphoma | 2.34 | (2.31, 2.38) | 2.47 | (2.43, 2.50) | 1.28 | (1.21, 1.36) |
| Myeloma | 0.75 | (0.73, 0.76) | 0.71 | (0.69, 0.73) | 1.15 | (1.08, 1.22) |
| Leukemia | 1.57 | (1.54, 1.60) | 1.65 | (1.62, 1.68) | 0.97 | (0.91, 1.05) |
| Acute Lymphocytic Leukemia | 0.14 | (0.13, 0.15) | 0.15 | (0.14, 0.16) | 0.08 | (0.07, 0.10) |
| Chronic Lymphocytic Leukemia | 0.61 | (0.59, 0.63) | 0.65 | (0.63, 0.67) | 0.35 | (0.31, 0.40) |
| Acute Myeloid Leukemia | 0.43 | (0.42, 0.45) | 0.45 | (0.43, 0.47) | 0.27 | (0.23, 0.31) |
| Chronic Myeloid Leukemia | 0.20 | (0.19, 0.21) | 0.20 | (0.19, 0.21) | 0.14 | (0.12, 0.17) |
| Kaposi Sarcoma | 0.08 | (0.08, 0.09) | 0.07 | (0.07, 0.08) | 0.14 | (0.12, 0.16) |
| Mesothelioma | 0.20 | (0.19, 0.21) | 0.22 | (0.21, 0.24) | 0.09 | (0.07, 0.12) |

Devcan Version 6.6.0, October 2011, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.15 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Males, 17 SEER Areas, 2006-2008

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|--|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 38.19 (37.63, 38.78) | 27.60 (25.87, 29.64) | 40.20 (39.65, 40.76) |
| Invasive and In Situ | 38.49 (37.92, 39.08) | 27.92 (26.17, 29.97) | 40.64 (40.10, 41.21) |
| Oral Cavity and Pharynx | 1.17 (1.09, 1.27) | 0.99 (0.58, 1.89) | 0.91 (0.84, 1.01) |
| Esophagus | 0.50 (0.45, 0.58) | 0.59 (0.39, 1.32) | 0.56 (0.50, 0.63) |
| Stomach | 2.21 (2.07, 2.36) | 1.29 (0.96, 2.09) | 1.79 (1.66, 1.93) |
| Colon and Rectum | 5.49 (5.28, 5.71) | 3.70 (3.16, 4.63) | 5.15 (4.96, 5.37) |
| Invasive and In Situ | 5.70 (5.49, 5.93) | 3.82 (3.28, 4.76) | 5.36 (5.16, 5.58) |
| Liver and Intrahepatic Bile Duct | 2.54 (2.41, 2.68) | 1.64 (1.30, 2.42) | 1.77 (1.68, 1.88) |
| Pancreas | 1.50 (1.38, 1.65) | 1.05 (0.73, 1.85) | 1.40 (1.30, 1.51) |
| Larynx | 0.28 (0.24, 0.35) | 0.28 (0.16, 1.01) | 0.53 (0.48, 0.61) |
| Invasive and In Situ | 0.31 (0.26, 0.38) | 0.30 (0.17, 1.02) | 0.57 (0.51, 0.65) |
| Lung and Bronchus | 7.11 (6.86, 7.38) | 4.97 (4.19, 6.12) | 5.05 (4.84, 5.27) |
| Melanoma of the Skin | 0.18 (0.14, 0.23) | 0.27 (0.15, 0.99) | 0.53 (0.46, 0.62) |
| Invasive and In Situ | 0.20 (0.17, 0.26) | 0.59 (0.36, 1.35) | 0.78 (0.70, 0.89) |
| Breast | 0.08 (0.06, 0.13) | 0.11 (0.04, 0.85) | 0.08 (0.06, 0.13) |
| Invasive and In Situ | 0.09 (0.07, 0.14) | 0.11 (0.04, 0.85) | 0.09 (0.07, 0.14) |
| Prostate | 11.46 (11.16, 11.77) | 7.43 (6.59, 8.62) | 14.93 (14.63, 15.26) |
| Testis | 0.13 (0.11, 0.17) | 0.28 (0.20, 0.98) | 0.32 (0.30, 0.37) |
| Urinary Bladder (Invasive and In Situ) | 2.25 (2.10, 2.42) | 1.21 (0.90, 2.00) | 2.50 (2.35, 2.68) |
| Kidney and Renal Pelvis | 1.32 (1.23, 1.44) | 2.29 (1.74, 3.27) | 2.04 (1.95, 2.16) |
| Brain and Other Nervous System | 0.45 (0.39, 0.52) | 0.34 (0.22, 1.05) | 0.56 (0.51, 0.64) |
| Thyroid | 0.50 (0.44, 0.57) | 0.20 (0.11, 0.92) | 0.39 (0.35, 0.46) |
| Hodgkin Lymphoma | 0.14 (0.12, 0.19) | 0.04 (0.01, 0.79) | 0.24 (0.22, 0.30) |
| Non-Hodgkin Lymphoma | 2.02 (1.89, 2.16) | 1.23 (0.91, 2.02) | 2.13 (2.02, 2.26) |
| Myeloma | 0.55 (0.48, 0.63) | 0.57 (0.21, 1.50) | 0.71 (0.64, 0.80) |
| Leukemia | 1.02 (0.93, 1.12) | 0.84 (0.55, 1.62) | 1.32 (1.21, 1.46) |
| Acute Lymphocytic Leukemia | 0.12 (0.09, 0.17) | 0.08 (0.04, 0.81) | 0.19 (0.17, 0.24) |
| Chronic Lymphocytic Leukemia | 0.20 (0.15, 0.27) | 0.22 (0.10, 0.96) | 0.35 (0.28, 0.44) |
| Acute Myeloid Leukemia | 0.43 (0.37, 0.50) | 0.20 (0.11, 0.92) | 0.40 (0.34, 0.49) |
| Chronic Myeloid Leukemia | 0.17 (0.14, 0.22) | 0.19 (0.05, 0.95) | 0.18 (0.15, 0.24) |
| Kaposi Sarcoma | 0.03 (0.02, 0.07) | 0.02 (0.00, 0.78) | 0.12 (0.09, 0.18) |
| Mesothelioma | 0.08 (0.05, 0.12) | 0.16 (0.06, 0.90) | 0.19 (0.15, 0.25) |

Devcan Version 6.6.0, October 2011, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

^a Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 17 SEER Areas, 2006-2008

| Site | All Races | | Whites | | Blacks | |
|--|-----------|------------------|---------|------------------|---------|------------------|
| | Percent | (95% C.I.) | Percent | (95% C.I.) | Percent | (95% C.I.) |
| All Sites | 38.08 | (37.96, 38.21) | 38.83 | (38.69, 38.97) | 33.43 | (33.06, 33.80) |
| Invasive and In Situ | 41.38 | (41.25, 41.51) | 42.17 | (42.03, 42.31) | 35.73 | (35.34, 36.11) |
| Oral Cavity and Pharynx | 0.67 | (0.65, 0.68) | 0.68 | (0.66, 0.70) | 0.47 | (0.43, 0.52) |
| Esophagus | 0.24 | (0.23, 0.25) | 0.24 | (0.23, 0.25) | 0.27 | (0.24, 0.31) |
| Stomach | 0.67 | (0.66, 0.69) | 0.57 | (0.55, 0.59) | 0.96 | (0.89, 1.03) |
| Colon and Rectum | 4.91 | (4.87, 4.96) | 4.84 | (4.79, 4.89) | 5.15 | (5.00, 5.30) |
| Invasive and In Situ | 5.12 | (5.07, 5.16) | 5.02 | (4.97, 5.07) | 5.44 | (5.29, 5.60) |
| Liver and Intrahepatic Bile Duct | 0.49 | (0.47, 0.50) | 0.42 | (0.40, 0.43) | 0.47 | (0.43, 0.52) |
| Pancreas | 1.45 | (1.42, 1.47) | 1.42 | (1.39, 1.44) | 1.66 | (1.58, 1.75) |
| Larynx | 0.14 | (0.13, 0.15) | 0.15 | (0.14, 0.15) | 0.17 | (0.15, 0.20) |
| Invasive and In Situ | 0.15 | (0.14, 0.16) | 0.16 | (0.15, 0.17) | 0.18 | (0.15, 0.20) |
| Lung and Bronchus | 6.33 | (6.28, 6.39) | 6.64 | (6.59, 6.70) | 5.56 | (5.41, 5.71) |
| Melanoma of the Skin | 1.57 | (1.55, 1.59) | 1.83 | (1.80, 1.86) | 0.09 | (0.07, 0.12) |
| Invasive and In Situ | 2.56 | (2.53, 2.59) | 2.94 | (2.90, 2.97) | 0.11 | (0.09, 0.14) |
| Breast | 12.29 | (12.23, 12.36) | 12.67 | (12.59, 12.74) | 10.58 | (10.38, 10.77) |
| Invasive and In Situ | 14.78 | (14.71, 14.85) | 15.16 | (15.08, 15.24) | 12.75 | (12.54, 12.97) |
| Cervix Uteri | 0.68 | (0.67, 0.70) | 0.66 | (0.64, 0.68) | 0.84 | (0.79, 0.89) |
| Corpus and Uterus, NOS | 2.61 | (2.58, 2.64) | 2.72 | (2.69, 2.75) | 2.10 | (2.02, 2.19) |
| Invasive and In Situ | 2.64 | (2.61, 2.67) | 2.75 | (2.71, 2.78) | 2.13 | (2.04, 2.22) |
| Ovary ^a | 1.40 | (1.38, 1.43) | 1.48 | (1.45, 1.50) | 0.99 | (0.92, 1.05) |
| Urinary Bladder (Invasive and In Situ) | 1.15 | (1.13, 1.18) | 1.23 | (1.20, 1.25) | 0.79 | (0.73, 0.86) |
| Kidney and Renal Pelvis | 1.19 | (1.17, 1.21) | 1.23 | (1.21, 1.25) | 1.17 | (1.10, 1.24) |
| Brain and Other Nervous System | 0.53 | (0.52, 0.55) | 0.58 | (0.57, 0.60) | 0.30 | (0.27, 0.34) |
| Thyroid | 1.44 | (1.42, 1.46) | 1.51 | (1.49, 1.53) | 0.79 | (0.74, 0.84) |
| Hodgkin Lymphoma | 0.21 | (0.21, 0.22) | 0.23 | (0.22, 0.24) | 0.18 | (0.16, 0.20) |
| Non-Hodgkin Lymphoma | 1.94 | (1.92, 1.97) | 2.05 | (2.02, 2.08) | 1.15 | (1.08, 1.22) |
| Myeloma | 0.56 | (0.55, 0.58) | 0.51 | (0.49, 0.53) | 1.04 | (0.97, 1.10) |
| Leukemia | 1.14 | (1.12, 1.16) | 1.19 | (1.17, 1.21) | 0.75 | (0.70, 0.81) |
| Acute Lymphocytic Leukemia | 0.11 | (0.11, 0.12) | 0.13 | (0.12, 0.13) | 0.05 | (0.04, 0.07) |
| Chronic Lymphocytic Leukemia | 0.40 | (0.39, 0.41) | 0.43 | (0.41, 0.44) | 0.20 | (0.17, 0.23) |
| Acute Myeloid Leukemia | 0.36 | (0.35, 0.37) | 0.36 | (0.35, 0.38) | 0.29 | (0.26, 0.33) |
| Chronic Myeloid Leukemia | 0.14 | (0.13, 0.14) | 0.14 | (0.13, 0.15) | 0.11 | (0.09, 0.14) |
| Kaposi Sarcoma | 0.01 | (0.01, 0.02) | 0.01 | (0.01, 0.01) | 0.02 | (0.01, 0.03) |
| Mesothelioma | 0.06 | (0.05, 0.06) | 0.06 | (0.06, 0.07) | 0.03 | (0.02, 0.05) |

Devcan Version 6.6.0, October 2011, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

^a Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 17 SEER Areas, 2006-2008

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|--|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 33.67 (33.17, 34.19) | 28.12 (26.57, 29.87) | 34.69 (34.25, 35.14) |
| Invasive and In Situ | 36.16 (35.65, 36.69) | 29.24 (27.67, 31.00) | 36.79 (36.34, 37.25) |
| Oral Cavity and Pharynx | 0.61 (0.55, 0.70) | 0.63 (0.36, 1.20) | 0.51 (0.46, 0.58) |
| Esophagus | 0.23 (0.18, 0.30) | 0.38 (0.22, 0.86) | 0.15 (0.13, 0.20) |
| Stomach | 1.55 (1.43, 1.68) | 0.77 (0.55, 1.28) | 1.21 (1.12, 1.31) |
| Colon and Rectum | 5.04 (4.83, 5.27) | 4.21 (3.59, 5.06) | 4.39 (4.22, 4.57) |
| Invasive and In Situ | 5.21 (5.00, 5.44) | 4.39 (3.76, 5.25) | 4.57 (4.40, 4.76) |
| Liver and Intrahepatic Bile Duct | 1.31 (1.20, 1.43) | 0.85 (0.61, 1.37) | 0.99 (0.91, 1.09) |
| Pancreas | 1.62 (1.48, 1.77) | 1.33 (1.00, 1.91) | 1.66 (1.55, 1.79) |
| Larynx | 0.05 (0.03, 0.10) | 0.11 (0.04, 0.56) | 0.07 (0.05, 0.10) |
| Invasive and In Situ | 0.06 (0.03, 0.11) | 0.12 (0.05, 0.57) | 0.07 (0.06, 0.10) |
| Lung and Bronchus | 4.39 (4.19, 4.60) | 4.28 (3.68, 5.10) | 3.66 (3.51, 3.82) |
| Melanoma of the Skin | 0.13 (0.10, 0.18) | 0.34 (0.21, 0.79) | 0.50 (0.45, 0.55) |
| Invasive and In Situ | 0.18 (0.15, 0.23) | 0.46 (0.30, 0.92) | 0.72 (0.66, 0.79) |
| Breast | 9.91 (9.68, 10.15) | 7.04 (6.36, 7.92) | 9.73 (9.53, 9.95) |
| Invasive and In Situ | 12.46 (12.21, 12.72) | 8.02 (7.31, 8.93) | 11.49 (11.27, 11.72) |
| Cervix Uteri | 0.71 (0.65, 0.79) | 0.60 (0.45, 1.06) | 1.10 (1.04, 1.17) |
| Corpus and Uterus, NOS | 1.98 (1.89, 2.09) | 1.76 (1.44, 2.33) | 2.13 (2.03, 2.23) |
| Invasive and In Situ | 1.99 (1.90, 2.10) | 1.76 (1.44, 2.33) | 2.15 (2.05, 2.25) |
| Ovary ^c | 1.15 (1.07, 1.25) | 1.25 (0.93, 1.83) | 1.38 (1.30, 1.47) |
| Urinary Bladder (Invasive and In Situ) | 0.65 (0.57, 0.75) | 0.45 (0.25, 0.96) | 0.80 (0.72, 0.88) |
| Kidney and Renal Pelvis | 0.78 (0.71, 0.87) | 1.47 (1.15, 2.05) | 1.36 (1.28, 1.45) |
| Brain and Other Nervous System | 0.37 (0.31, 0.44) | 0.29 (0.18, 0.74) | 0.51 (0.47, 0.57) |
| Thyroid | 1.61 (1.53, 1.70) | 0.78 (0.60, 1.25) | 1.40 (1.33, 1.48) |
| Hodgkin Lymphoma | 0.10 (0.08, 0.14) | 0.12 (0.03, 0.59) | 0.21 (0.18, 0.25) |
| Non-Hodgkin Lymphoma | 1.60 (1.48, 1.74) | 1.11 (0.82, 1.67) | 1.98 (1.88, 2.10) |
| Myeloma | 0.41 (0.36, 0.48) | 0.40 (0.25, 0.87) | 0.60 (0.55, 0.67) |
| Leukemia | 0.81 (0.73, 0.91) | 0.57 (0.40, 1.05) | 0.95 (0.89, 1.02) |
| Acute Lymphocytic Leukemia | 0.10 (0.08, 0.14) | 0.06 (0.02, 0.51) | 0.19 (0.18, 0.23) |
| Chronic Lymphocytic Leukemia | 0.13 (0.09, 0.19) | 0.03 (0.00, 0.49) | 0.20 (0.17, 0.25) |
| Acute Myeloid Leukemia | 0.39 (0.34, 0.47) | 0.30 (0.18, 0.76) | 0.31 (0.27, 0.36) |
| Chronic Myeloid Leukemia | 0.09 (0.07, 0.14) | 0.09 (0.04, 0.54) | 0.12 (0.10, 0.16) |
| Kaposi Sarcoma | 0.00 (0.00, 0.05) | 0.02 (0.00, 0.48) | 0.02 (0.01, 0.05) |
| Mesothelioma | 0.03 (0.02, 0.07) | 0.07 (0.02, 0.53) | 0.06 (0.05, 0.10) |

Devcan Version 6.6.0, October 2011, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

^a Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^c Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.